These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 22807514

  • 1. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
    Albiges L, Molinie V, Escudier B.
    Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
    Pal SK, Figlin RA.
    Target Oncol; 2011 Mar; 6(1):5-16. PubMed ID: 21484496
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R, Boni JP, Ravaud A.
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [Abstract] [Full Text] [Related]

  • 6. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. mTOR inhibitors in advanced renal cell carcinoma.
    Voss MH, Molina AM, Motzer RJ.
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ.
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [Abstract] [Full Text] [Related]

  • 12. Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
    Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G.
    Eur J Cancer; 2017 Sep; 83():237-246. PubMed ID: 28756136
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K, Yoshino H, Okamura S, Tsuruda M, Osako Y, Sakaguchi T, Sugita S, Tatarano S, Nakagawa M, Enokida H.
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [Abstract] [Full Text] [Related]

  • 15. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A, Redondo Sánchez A, Espinosa Arranz E, Zamora Auñón P, Castelo Fernández B, González Barón M.
    Urol Oncol; 2012 May; 30(4):356-61. PubMed ID: 20207176
    [Abstract] [Full Text] [Related]

  • 16. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK, Quinn DI.
    Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
    [Abstract] [Full Text] [Related]

  • 17. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, Guo J.
    BMC Cancer; 2014 May 28; 14():376. PubMed ID: 24886512
    [Abstract] [Full Text] [Related]

  • 18. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.
    Barthélémy P, Hoch B, Chevreau C, Joly F, Laguerre B, Lokiec F, Duclos B.
    Crit Rev Oncol Hematol; 2013 Oct 28; 88(1):42-56. PubMed ID: 23523056
    [Abstract] [Full Text] [Related]

  • 19. Clinical development of mTor inhibitors for renal cancer.
    Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, Barni S.
    Expert Opin Investig Drugs; 2017 Nov 28; 26(11):1229-1237. PubMed ID: 28952411
    [Abstract] [Full Text] [Related]

  • 20. Expression level of phosphorylated-4E-binding protein 1 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with mammalian target of rapamycin inhibitors.
    Nishikawa M, Miyake H, Harada K, Fujisawa M.
    Med Oncol; 2014 Jan 28; 31(1):792. PubMed ID: 24307346
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.